Arcturus Therapeutics Issues Statement

SAN DIEGO, Feb. 06, 2018 -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today issued the following statement in response to the 13D filing issued by Joseph E. Payne:

We are aware of the 13D filing by Joseph E. Payne, Arcturus’ former President and Chief Executive Officer, who was terminated on February 1, 2018 for conduct that our Board of Directors deemed to be contrary to the best interests of the Company and its shareholders. Our Board believes that Mr. Payne has demonstrated that he is unable to put the needs of the company and its shareholders ahead of his own self-interest.

Our Board of Directors and management team are committed to acting in the best interest of shareholders and enhancing long-term value for all shareholders, and we will continue to take the actions that we believe will enable us to achieve this objective.

About Arcturus Therapeutics Ltd.

Founded in 2013 and based in San Diego, Arcturus Therapeutics Ltd. (NASDAQ:ARCT) is an RNA medicines company with enabling technologies – UNA Oligomer chemistry and LUNAR™ lipid-mediated delivery. Arcturus’s diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis, and vaccines. Arcturus’s versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. Arcturus owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology including UNA Oligomers, which are covered by its extensive patent portfolio (120 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’s proprietary UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes. Arcturus’s commitment to the development of novel RNA therapeutics has led to partnerships with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, Synthetic Genomics Inc., and Cystic Fibrosis Foundation Therapeutics Inc. For more information, visit www.ArcturusRx.com, the content of which is not incorporated herein by reference.

Media Contacts
Arcturus Therapeutics
+1 (858) 900-2660
[email protected]

Investor Contacts
Michael Wood
LifeSci Advisors LLC
+1 (646) 597-6979
[email protected]

Andrew Brimmer / Trevor Gibbons
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449